Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma

Nature Genetics

Volumn 48, Issue 12, 2016, Pages 1500-1507

  Hao, Jia Jie ^a   Lin, De Chen ^b,c   Dinh, Huy Q ^d   Mayakonda, Anand ^e   Jiang, Yan Yi ^e   Chang, Chen ^a   Jiang, Ye ^a   Lu, Chen Chen ^a   Shi, Zhi Zhou ^f   Xu, Xin ^a   Zhang, Yu ^a   Cai, Yan ^a   Wang, Jin Wu ^g   Zhan, Qi Min ^a   Wei, Wen Qiang ^a   Berman, Benjamin P ^d   Wang, Ming Rong ^a   Koeffler, H Phillip ^b,e,h  

^a CANCER HOSPITAL   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g Linzhou Cancer Hospital   (China)

^h NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TUMOR PROTEIN;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; CLONAL EVOLUTION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE DOSAGE; GENE LOCATION; GENE STRUCTURE; GENE TARGETING; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; INTRATUMORAL HETEROGENEITY; MALE; MTOR ONCOGENE; NFE2L2 ONCOGENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PHYLOGENETIC TREE; PIK3CA ONCOGENE; PRIORITY JOURNAL; SOMATIC MUTATION; SPATIOTEMPORAL ANALYSIS; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE KMT2D; TUMOR SUPPRESSOR GENE TP53; TUMOR SUPPRESSOR GENE ZNF750; WHOLE EXOME SEQUENCING; CELL CLONE; COHORT ANALYSIS; ESOPHAGUS TUMOR; EXOME; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MUTATION; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CLONAL EVOLUTION; CLONE CELLS; COHORT STUDIES; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; EXOME; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASM PROTEINS;

EID: 84991735080     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3683     Document Type: Article

References (80)

1. Torre, L.A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015
2. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015
3. Enzinger, P.C. & Mayer, R.J. Esophageal cancer. N. Engl. J. Med. 349, 2241-2252 (2003
4. Agrawal, N. et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2, 899-905 (2012
5. Song, Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91-95 (2014
6. Lin, D.C. et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 46, 467-473 (2014
7. Gao, Y.B. et al. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097-1102 (2014
8. Zhang, L. et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 96, 597-611 (2015
9. Cheng, C. et al. Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 98, 256-274 (2016
10. McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15-26 (2015
11. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004
12. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014
13. McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015
14. Durinck, S. et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 1, 137-143 (2011
15. Shah, S.P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012
16. Lohr, J.G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014
17. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013
18. Shi, Z.Z. et al. Consistent and differential genetic aberrations between esophageal dysplasia and squamous cell carcinoma detected by array comparative genomic hybridization. Clin. Cancer Res. 19, 5867-5878 (2013
19. Shang, L. et al. ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction. Oncotarget 7, 24374-24382 (2016
20. Britschgi, A. et al. Calcium-Activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc. Natl. Acad. Sci. USA 110, E1026-E1034 (2013
21. Luo, M.L. et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 66, 11690-11699 (2006
22. Lu, P. et al. Genome-wide gene expression profile analyses identify CTTN as a potential prognostic marker in esophageal cancer. PLoS One 9, e88918 (2014
23. de Bruin, E.C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014
24. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014
25. Murugaesu, N. et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5, 821-831 (2015
26. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B.S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016
27. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
28. Toh, Y., Egashira, A. & Yamamoto, M. Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma. Gen. Thorac. Cardiovasc. Surg. 61, 262-269 (2013
29. Agarwal, R. et al. Epigenomic program of Barrett's-Associated neoplastic progression reveals possible involvement of insulin signaling pathways. Endocr. Relat. Cancer 19, L5-L9 (2012
30. Alvarez, H. et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 7, e1001356 (2011
31. Brocks, D. et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 8, 798-806 (2014
32. Mazor, T. et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28, 307-317 (2015
33. Robinson, D.F. & Foulds, L.R. Comparison of phylogenetic trees. Math. Biosci. 53, 131-147 (1981
34. Oricchio, E. et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147, 554-564 (2011
35. López-Nieva, P. et al. EPHA7, a new target gene for 6q deletion in T-cell lymphoblastic lymphomas. Carcinogenesis 33, 452-458 (2012
36. Yu, J. et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136, 640-651.e1 (2009
37. Zhao, Y. et al. A novel Wnt regulatory axis in endometrioid endometrial cancer. Cancer Res. 74, 5103-5117 (2014
38. Saulnier, A. et al. Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers. Int. J. Cancer 130, 2484-2494 (2012
39. Mercier, P.L. et al. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol. Oncol. 5, 438-453 (2011
40. Bergman, Y. & Cedar, H. DNA methylation dynamics in health and disease. Nat. Struct. Mol. Biol. 20, 274-281 (2013
41. Quante, T. & Bird, A. Do short, frequent DNA sequence motifs mould the epigenome? Nat. Rev. Mol. Cell Biol. 17, 257-262 (2016
42. Baylin, S.B. & Jones, P.A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011
43. Lay, F.D. et al. The role of DNA methylation in directing the functional organization of the cancer epigenome. Genome Res. 25, 467-477 (2015
44. Irizarry, R.A. et al. The human colon cancer methylome shows similar hypo-And hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178-186 (2009
45. Doi, A. et al. Differential methylation of tissue-And cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41, 1350-1353 (2009
46. Gharwan, H. & Groninger, H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat. Rev. Clin. Oncol. 13, 209-227 (2016
47. Gerlinger, M. et al. Cancer: evolution within a lifetime. Annu. Rev. Genet. 48, 215-236 (2014
48. Cao, W. et al. Multiple region whole-exome sequencing reveals dramatically evolving intratumor genomic heterogeneity in esophageal squamous cell carcinoma. Oncogenesis 4, e175 (2015
49. Yap, T.A., Gerlinger, M., Futreal, P.A., Pusztai, L. & Swanton, C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 4, 127ps10 (2012
50. Wang, J. et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24, 5637-5647 (2005
51. Kiehl, S. et al. ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. Sci. Rep. 4, 6899 (2014
52. Jao, T.M. et al. Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis. Int. J. Cancer 135, 2593-2603 (2014
53. Narayan, G. et al. PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosom. Cancer 52, 1030-1041 (2013
54. Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115-132 (2016
55. Faust, G.G. & Hall, I.M. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics 30, 2503-2505 (2014
56. Van der Auwera, G.A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1-11.10.33 (2013
57. Koboldt, D.C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012
58. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009
59. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010
60. Stachler, M.D. et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat. Genet. 47, 1047-1055 (2015
61. Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004
62. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012
63. Kumar, P., Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073-1081 (2009
64. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010
65. Adzhubei, I., Jordan, D.M. & Sunyaev, S.R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. Chapter 7, Unit 7.20 (2013
66. Triche, T.J. Jr., Weisenberger, D.J., Van Den Berg, D., Laird, P.W. & Siegmund, K.D. Low-level processing of Illumina Infinium DNA Methylation BeadArrays. Nucleic Acids Res. 41, e90 (2013
67. Desper, R. & Gascuel, O. Fast and accurate phylogeny reconstruction algorithms based on the minimum-evolution principle. J. Comput. Biol. 9, 687-705 (2002
68. Takahashi, T. et al. Estimation of the fraction of cancer cells in a tumor DNA sample using DNA methylation. PLoS One 8, e82302 (2013
69. Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013
70. Pagés, F. et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27, 5944-5951 (2009
71. de Miranda, N.F. et al. Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. Clin. Cancer Res. 18, 1237-1245 (2012
72. Punt, S. et al. Whole-transcriptome analysis of flow-sorted cervical cancer samples reveals that B cell expressed TCL1A is correlated with improved survival. Oncotarget 6, 38681-38694 (2015
73. Gorter, A., Prins, F., van Diepen, M., Punt, S. & van der Burg, S.H. The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J. Transl. Med. 13, 295 (2015
74. Reinius, L.E. et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One 7, e41361 (2012
75. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014
76. Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550-563 (2016
77. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015
78. Wu, H., Caffo, B., Jaffee, H.A., Irizarry, R.A. & Feinberg, A.P. Redefining CpG islands using hidden Markov models. Biostatistics 11, 499-514 (2010
79. Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317-330 (2015
80. Song, Q. et al. A reference methylome database and analysis pipeline to facilitate integrative and comparative epigenomics. PLoS One 8, e81148 (2013).